Strasbourg, France, April 21, 2015 – Transgene SA (Euronext: TNG) today announced that new pre-clinical data for two of its programs – TG4010 and TG3003 – were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in Philadelphia, PA USA.
New pre-clinical data support potential combinations of TG4010 and immune checkpoint inhibitors
Data with TG3003 anti-CD115 monoclonal antibody support biological activity and differentiated mode of action
A third poster reviewing the clinical experience with Transgene’s MVA platform was also presented.
Copies of these posters can be found on Transgene’s website in the “Our Pipeline/Publications” section at http://www.transgene.fr/?page_id=10487#TG1050.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.58 (c)||1.98%||72 486|